Pulmovant — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Pulmovant is a private, pre-revenue biotech company based in San Diego, established to address high unmet needs in pulmonary diseases. Its lead asset, mosliciguat, is a potential first-in-class, once-daily inhaled sGC activator currently in clinical development for PH-ILD, with a mechanism that may offer vasodilatory, anti-inflammatory, and anti-fibrotic benefits. The company operates under the Roivant Sciences umbrella, benefiting from its operational model and experienced leadership team, including CEO Drew Fromkin, to rapidly advance its pipeline. Pulmovant's strategy centers on creating a differentiated, inhaled treatment paradigm to improve outcomes for patients with challenging pulmonary conditions.

Pulmonary HypertensionInterstitial Lung Disease

Technology Platform

Inhaled delivery of soluble guanylate cyclase (sGC) activators targeting the NO-sGC-cGMP pathway for pulmonary diseases.

Opportunities

The primary opportunity is addressing the high unmet need in PH-ILD, where treatment options are severely limited.

Success with mosliciguat could establish a new, convenient standard of care.

The multi-modal mechanism also provides a platform for potential expansion into other pulmonary fibrotic and inflammatory diseases.

Risk Factors

Key risks include clinical trial failure of its sole lead asset, mosliciguat, in PH-ILD.

The company faces significant competition from other developers targeting similar indications.

As a single-asset, pre-revenue company, it is highly vulnerable to negative clinical data and dependent on continued funding from its parent organization.

Competitive Landscape

The competitive landscape for PH-ILD includes United Therapeutics' inhaled treprostinil (Tyvaso), the only approved therapy. Other competitors are developing oral therapies (e.g., sotatercept for PAH, exploring in ILD) and novel mechanisms. Pulmovant aims to differentiate with a first-in-class inhaled sGC activator, focusing on convenience and a potentially disease-modifying mechanism.

More companies in Small Molecule Drugs →More companies in United States →